tiprankstipranks
Advertisement
Advertisement

HROW Stock Latest News

Analyst Maintains Buy on Harrow Health, Keeps DCF-Based Price Target Unchanged at $63 on Strength of IHEEZO and Expanding Retina Portfolio
RatingsAnalyst Maintains Buy on Harrow Health, Keeps DCF-Based Price Target Unchanged at $63 on Strength of IHEEZO and Expanding Retina Portfolio
2d ago
HROW
Harrow Health Earnings Call Signals Growth Amid Risks
PremiumCompany Announcements
Harrow Health Earnings Call Signals Growth Amid Risks
3d ago
HROW
Harrow: Strong Iheezo Demand and Confident 2026 Guidance Support Buy Rating Despite Near-Term Miss
PremiumRatings
Harrow: Strong Iheezo Demand and Confident 2026 Guidance Support Buy Rating Despite Near-Term Miss
12d ago
HROW
Harrow Health Sees Strong Q2 Growth, Reaffirms 2026 Outlook
PremiumCompany Announcements
Harrow Health Sees Strong Q2 Growth, Reaffirms 2026 Outlook
12d ago
8K
HROW
Harrow reports Q2 EPS (46c), consensus (24c)
PremiumThe Fly
Harrow reports Q2 EPS (46c), consensus (24c)
12d ago
HROW
Is HROW a Buy, Before Earnings?
PremiumPre-EarningsIs HROW a Buy, Before Earnings?
15d ago
HROW
Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M
Premium
The Fly
Harrow to acquire global rights to Tyrvaya from Viatris for up to $100M
17d ago
HROW
VTRS
Harrow Health Acquires Global Rights to TYRVAYA Nasal Spray
Premium
Company Announcements
Harrow Health Acquires Global Rights to TYRVAYA Nasal Spray
17d ago
8K
HROW
Harrow: Operational Stabilization and Retina Growth Support Buy Rating with Unchanged $63 Price Target
PremiumRatings
Harrow: Operational Stabilization and Retina Growth Support Buy Rating with Unchanged $63 Price Target
1M ago
HROW
Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data
PremiumThe Fly
Harrow and Samsung Bioepis present interim BYOOVIZ post-marketing data
1M ago
HROW
Analyst Reaffirms Buy on Harrow Health, Citing Expanding Ophthalmic Franchise and Long-Term Growth Pipeline
PremiumRatings
Analyst Reaffirms Buy on Harrow Health, Citing Expanding Ophthalmic Franchise and Long-Term Growth Pipeline
2M ago
HROW
Harrow announces commercial launch of Byooviz in the U.S.
PremiumThe Fly
Harrow announces commercial launch of Byooviz in the U.S.
2M ago
HROW
Harrow announces commercial launch of BYOOVIZ in U.S.
PremiumThe FlyHarrow announces commercial launch of BYOOVIZ in U.S.
2M ago
HROW
Harrow Health Stockholders Approve Directors and Executive Pay
Premium
Company Announcements
Harrow Health Stockholders Approve Directors and Executive Pay
2M ago
8K
HROW
Analyst Reiterates Buy on Harrow Health, Citing Verkazia Relaunch and Upcoming Iheezo Data as Key Growth Catalysts
Premium
Ratings
Analyst Reiterates Buy on Harrow Health, Citing Verkazia Relaunch and Upcoming Iheezo Data as Key Growth Catalysts
2M ago
HROW
Harrow Health Releases June 2026 Investor Presentation Update
PremiumCompany Announcements
Harrow Health Releases June 2026 Investor Presentation Update
3M ago
8K
HROW
Harrow CEO buys $302K, CFO buys $104.7K in common stock
PremiumThe Fly
Harrow CEO buys $302K, CFO buys $104.7K in common stock
3M ago
HROW
Harrow price target lowered to $60 from $65 at B. Riley
PremiumThe Fly
Harrow price target lowered to $60 from $65 at B. Riley
3M ago
HROW
Harrow price target lowered to $88 from $91 at Cantor Fitzgerald
PremiumThe Fly
Harrow price target lowered to $88 from $91 at Cantor Fitzgerald
3M ago
HROW
Analyst Reiterates Buy Rating and Maintains $63 Price Target as Temporary Headwinds Mask Strengthening Ophthalmic Growth Outlook
PremiumRatingsAnalyst Reiterates Buy Rating and Maintains $63 Price Target as Temporary Headwinds Mask Strengthening Ophthalmic Growth Outlook
3M ago
HROW
Harrow Health Earnings Call Highlights Growth Amid Headwinds
Premium
Company Announcements
Harrow Health Earnings Call Highlights Growth Amid Headwinds
3M ago
HROW
Closing Bell Movers: Hims & Hers down 12% on earnings miss
Premium
The Fly
Closing Bell Movers: Hims & Hers down 12% on earnings miss
3M ago
GTM
ASTS

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >